Global Anti-CD19 Market

Anti-CD19 Comprehensive Study by Type (Antibody Drug Conjugates, Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies), Engineered Antibodies, Bispecific Antibody (BsAb)), Application (Hospitals, Laboratories) Players and Region - Global Market Outlook to 2028

Anti-CD19 Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Anti-CD19 Market Scope
CD19 is found on B-lineage cells and follicular dendritic cells, and it is important in B-cell malignancies and autoimmune disorders. As a result, numerous monoclonal antibodies have been developed to target it (mAbs). Chemotherapy has long been recognised as one of the most effective anticancer treatments for tumours with a high proliferation rate. Anti-CD19 mAbs produced for treating CD19-positive lymphomas and autoimmune disorders, on the other hand, would be among the pharmaceutical industry's most unique areas of research and development. Technical progress in biotech industry along with other variables have facilitated growth in Anti CD19 market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca (United Kingdom), Serum Institute of India (India), Bristol-Myers Squibb Company (United States), Morphosys AG (Germany), Xencor, Inc (United States), Seattle Genetics, Inc. (United States), Affimed GmbH (Germany), Bayer AG (Germany), Bellicum Phamaceuticals, Inc. (United States) and Cellular Biomedicine Group (United States)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

AstraZeneca (United Kingdom), Serum Institute of India (India), Bristol-Myers Squibb Company (United States), Morphosys AG (Germany), Xencor, Inc (United States), Seattle Genetics, Inc. (United States), Affimed GmbH (Germany), Bayer AG (Germany), Bellicum Phamaceuticals, Inc. (United States) and Cellular Biomedicine Group (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Amgen Inc. (United States), Sanofi S.A. (France), Bharat Biotech (India) and Bio-Rad Laboratories, Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Anti-CD19 market by Type , by Application (Hospitals and Laboratories) and Region with country level break-up.

On the basis of geography, the market of Anti-CD19 has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In June, 2019 - CASI Pharmaceuticals Acquired Worldwide Rights to Commercialize anti-CD19 T-cell Therapy from Juventas Cell Therapy Ltd. Juventas will Continue to Develop CNCT19 Under the Terms of The Agreement, With CASI Serving on The Program's Steering Committee. Payment Of Future Development Milestones and Sales Royalties Will Be the Responsibility of CASI.
In April, 2021 - ADC Therapeutics Received US FDA Approval for Anti-CD19 Blood Cancer Med Zynlonta as a Solo Treatment for Adult Patients with Relapsed or Refractory DLBCL After Two Prior Lines of Therapy. The Approval was Followed by a series of Clinical Trials.


Influencing Trend:
Emergence of Advance Cell Technology Procedures

Market Growth Drivers:
Technical Progress in Biotechnology Industry and Rising Demand for Antibody Drug Conjugates

Challenges:
High Initial Investments

Restraints:
Lack of Trained Professionals

Opportunities:
Increasing Demand across Developing Regions

Key Target Audience
Anti-CD19 Product Manufactures, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Antibody Drug Conjugates
  • Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies)
  • Engineered Antibodies
  • Bispecific Antibody (BsAb)
By Application
  • Hospitals
  • Laboratories
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technical Progress in Biotechnology Industry
      • 3.2.2. Rising Demand for Antibody Drug Conjugates
    • 3.3. Market Challenges
      • 3.3.1. High Initial Investments
    • 3.4. Market Trends
      • 3.4.1. Emergence of Advance Cell Technology Procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-CD19, by Type, Application and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-CD19 (Value)
      • 5.2.1. Global Anti-CD19 by: Type (Value)
        • 5.2.1.1. Antibody Drug Conjugates
        • 5.2.1.2. Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies)
        • 5.2.1.3. Engineered Antibodies
        • 5.2.1.4. Bispecific Antibody (BsAb)
      • 5.2.2. Global Anti-CD19 by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Laboratories
      • 5.2.3. Global Anti-CD19 Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Anti-CD19: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Serum Institute of India (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Myers Squibb Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Morphosys AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Xencor, Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Seattle Genetics, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Affimed GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bellicum Phamaceuticals, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cellular Biomedicine Group (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Anti-CD19 Sale, by Type, Application and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-CD19 (Value)
      • 7.2.1. Global Anti-CD19 by: Type (Value)
        • 7.2.1.1. Antibody Drug Conjugates
        • 7.2.1.2. Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies)
        • 7.2.1.3. Engineered Antibodies
        • 7.2.1.4. Bispecific Antibody (BsAb)
      • 7.2.2. Global Anti-CD19 by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Laboratories
      • 7.2.3. Global Anti-CD19 Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-CD19: by Type(USD Million)
  • Table 2. Anti-CD19 Antibody Drug Conjugates , by Region USD Million (2017-2022)
  • Table 3. Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies) , by Region USD Million (2017-2022)
  • Table 4. Anti-CD19 Engineered Antibodies , by Region USD Million (2017-2022)
  • Table 5. Anti-CD19 Bispecific Antibody (BsAb) , by Region USD Million (2017-2022)
  • Table 6. Anti-CD19: by Application(USD Million)
  • Table 7. Anti-CD19 Hospitals , by Region USD Million (2017-2022)
  • Table 8. Anti-CD19 Laboratories , by Region USD Million (2017-2022)
  • Table 9. South America Anti-CD19, by Country USD Million (2017-2022)
  • Table 10. South America Anti-CD19, by Type USD Million (2017-2022)
  • Table 11. South America Anti-CD19, by Application USD Million (2017-2022)
  • Table 12. Brazil Anti-CD19, by Type USD Million (2017-2022)
  • Table 13. Brazil Anti-CD19, by Application USD Million (2017-2022)
  • Table 14. Argentina Anti-CD19, by Type USD Million (2017-2022)
  • Table 15. Argentina Anti-CD19, by Application USD Million (2017-2022)
  • Table 16. Rest of South America Anti-CD19, by Type USD Million (2017-2022)
  • Table 17. Rest of South America Anti-CD19, by Application USD Million (2017-2022)
  • Table 18. Asia Pacific Anti-CD19, by Country USD Million (2017-2022)
  • Table 19. Asia Pacific Anti-CD19, by Type USD Million (2017-2022)
  • Table 20. Asia Pacific Anti-CD19, by Application USD Million (2017-2022)
  • Table 21. China Anti-CD19, by Type USD Million (2017-2022)
  • Table 22. China Anti-CD19, by Application USD Million (2017-2022)
  • Table 23. Japan Anti-CD19, by Type USD Million (2017-2022)
  • Table 24. Japan Anti-CD19, by Application USD Million (2017-2022)
  • Table 25. India Anti-CD19, by Type USD Million (2017-2022)
  • Table 26. India Anti-CD19, by Application USD Million (2017-2022)
  • Table 27. South Korea Anti-CD19, by Type USD Million (2017-2022)
  • Table 28. South Korea Anti-CD19, by Application USD Million (2017-2022)
  • Table 29. Taiwan Anti-CD19, by Type USD Million (2017-2022)
  • Table 30. Taiwan Anti-CD19, by Application USD Million (2017-2022)
  • Table 31. Australia Anti-CD19, by Type USD Million (2017-2022)
  • Table 32. Australia Anti-CD19, by Application USD Million (2017-2022)
  • Table 33. Rest of Asia-Pacific Anti-CD19, by Type USD Million (2017-2022)
  • Table 34. Rest of Asia-Pacific Anti-CD19, by Application USD Million (2017-2022)
  • Table 35. Europe Anti-CD19, by Country USD Million (2017-2022)
  • Table 36. Europe Anti-CD19, by Type USD Million (2017-2022)
  • Table 37. Europe Anti-CD19, by Application USD Million (2017-2022)
  • Table 38. Germany Anti-CD19, by Type USD Million (2017-2022)
  • Table 39. Germany Anti-CD19, by Application USD Million (2017-2022)
  • Table 40. France Anti-CD19, by Type USD Million (2017-2022)
  • Table 41. France Anti-CD19, by Application USD Million (2017-2022)
  • Table 42. Italy Anti-CD19, by Type USD Million (2017-2022)
  • Table 43. Italy Anti-CD19, by Application USD Million (2017-2022)
  • Table 44. United Kingdom Anti-CD19, by Type USD Million (2017-2022)
  • Table 45. United Kingdom Anti-CD19, by Application USD Million (2017-2022)
  • Table 46. Netherlands Anti-CD19, by Type USD Million (2017-2022)
  • Table 47. Netherlands Anti-CD19, by Application USD Million (2017-2022)
  • Table 48. Rest of Europe Anti-CD19, by Type USD Million (2017-2022)
  • Table 49. Rest of Europe Anti-CD19, by Application USD Million (2017-2022)
  • Table 50. MEA Anti-CD19, by Country USD Million (2017-2022)
  • Table 51. MEA Anti-CD19, by Type USD Million (2017-2022)
  • Table 52. MEA Anti-CD19, by Application USD Million (2017-2022)
  • Table 53. Middle East Anti-CD19, by Type USD Million (2017-2022)
  • Table 54. Middle East Anti-CD19, by Application USD Million (2017-2022)
  • Table 55. Africa Anti-CD19, by Type USD Million (2017-2022)
  • Table 56. Africa Anti-CD19, by Application USD Million (2017-2022)
  • Table 57. North America Anti-CD19, by Country USD Million (2017-2022)
  • Table 58. North America Anti-CD19, by Type USD Million (2017-2022)
  • Table 59. North America Anti-CD19, by Application USD Million (2017-2022)
  • Table 60. United States Anti-CD19, by Type USD Million (2017-2022)
  • Table 61. United States Anti-CD19, by Application USD Million (2017-2022)
  • Table 62. Canada Anti-CD19, by Type USD Million (2017-2022)
  • Table 63. Canada Anti-CD19, by Application USD Million (2017-2022)
  • Table 64. Mexico Anti-CD19, by Type USD Million (2017-2022)
  • Table 65. Mexico Anti-CD19, by Application USD Million (2017-2022)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Anti-CD19: by Type(USD Million)
  • Table 77. Anti-CD19 Antibody Drug Conjugates , by Region USD Million (2023-2028)
  • Table 78. Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies) , by Region USD Million (2023-2028)
  • Table 79. Anti-CD19 Engineered Antibodies , by Region USD Million (2023-2028)
  • Table 80. Anti-CD19 Bispecific Antibody (BsAb) , by Region USD Million (2023-2028)
  • Table 81. Anti-CD19: by Application(USD Million)
  • Table 82. Anti-CD19 Hospitals , by Region USD Million (2023-2028)
  • Table 83. Anti-CD19 Laboratories , by Region USD Million (2023-2028)
  • Table 84. South America Anti-CD19, by Country USD Million (2023-2028)
  • Table 85. South America Anti-CD19, by Type USD Million (2023-2028)
  • Table 86. South America Anti-CD19, by Application USD Million (2023-2028)
  • Table 87. Brazil Anti-CD19, by Type USD Million (2023-2028)
  • Table 88. Brazil Anti-CD19, by Application USD Million (2023-2028)
  • Table 89. Argentina Anti-CD19, by Type USD Million (2023-2028)
  • Table 90. Argentina Anti-CD19, by Application USD Million (2023-2028)
  • Table 91. Rest of South America Anti-CD19, by Type USD Million (2023-2028)
  • Table 92. Rest of South America Anti-CD19, by Application USD Million (2023-2028)
  • Table 93. Asia Pacific Anti-CD19, by Country USD Million (2023-2028)
  • Table 94. Asia Pacific Anti-CD19, by Type USD Million (2023-2028)
  • Table 95. Asia Pacific Anti-CD19, by Application USD Million (2023-2028)
  • Table 96. China Anti-CD19, by Type USD Million (2023-2028)
  • Table 97. China Anti-CD19, by Application USD Million (2023-2028)
  • Table 98. Japan Anti-CD19, by Type USD Million (2023-2028)
  • Table 99. Japan Anti-CD19, by Application USD Million (2023-2028)
  • Table 100. India Anti-CD19, by Type USD Million (2023-2028)
  • Table 101. India Anti-CD19, by Application USD Million (2023-2028)
  • Table 102. South Korea Anti-CD19, by Type USD Million (2023-2028)
  • Table 103. South Korea Anti-CD19, by Application USD Million (2023-2028)
  • Table 104. Taiwan Anti-CD19, by Type USD Million (2023-2028)
  • Table 105. Taiwan Anti-CD19, by Application USD Million (2023-2028)
  • Table 106. Australia Anti-CD19, by Type USD Million (2023-2028)
  • Table 107. Australia Anti-CD19, by Application USD Million (2023-2028)
  • Table 108. Rest of Asia-Pacific Anti-CD19, by Type USD Million (2023-2028)
  • Table 109. Rest of Asia-Pacific Anti-CD19, by Application USD Million (2023-2028)
  • Table 110. Europe Anti-CD19, by Country USD Million (2023-2028)
  • Table 111. Europe Anti-CD19, by Type USD Million (2023-2028)
  • Table 112. Europe Anti-CD19, by Application USD Million (2023-2028)
  • Table 113. Germany Anti-CD19, by Type USD Million (2023-2028)
  • Table 114. Germany Anti-CD19, by Application USD Million (2023-2028)
  • Table 115. France Anti-CD19, by Type USD Million (2023-2028)
  • Table 116. France Anti-CD19, by Application USD Million (2023-2028)
  • Table 117. Italy Anti-CD19, by Type USD Million (2023-2028)
  • Table 118. Italy Anti-CD19, by Application USD Million (2023-2028)
  • Table 119. United Kingdom Anti-CD19, by Type USD Million (2023-2028)
  • Table 120. United Kingdom Anti-CD19, by Application USD Million (2023-2028)
  • Table 121. Netherlands Anti-CD19, by Type USD Million (2023-2028)
  • Table 122. Netherlands Anti-CD19, by Application USD Million (2023-2028)
  • Table 123. Rest of Europe Anti-CD19, by Type USD Million (2023-2028)
  • Table 124. Rest of Europe Anti-CD19, by Application USD Million (2023-2028)
  • Table 125. MEA Anti-CD19, by Country USD Million (2023-2028)
  • Table 126. MEA Anti-CD19, by Type USD Million (2023-2028)
  • Table 127. MEA Anti-CD19, by Application USD Million (2023-2028)
  • Table 128. Middle East Anti-CD19, by Type USD Million (2023-2028)
  • Table 129. Middle East Anti-CD19, by Application USD Million (2023-2028)
  • Table 130. Africa Anti-CD19, by Type USD Million (2023-2028)
  • Table 131. Africa Anti-CD19, by Application USD Million (2023-2028)
  • Table 132. North America Anti-CD19, by Country USD Million (2023-2028)
  • Table 133. North America Anti-CD19, by Type USD Million (2023-2028)
  • Table 134. North America Anti-CD19, by Application USD Million (2023-2028)
  • Table 135. United States Anti-CD19, by Type USD Million (2023-2028)
  • Table 136. United States Anti-CD19, by Application USD Million (2023-2028)
  • Table 137. Canada Anti-CD19, by Type USD Million (2023-2028)
  • Table 138. Canada Anti-CD19, by Application USD Million (2023-2028)
  • Table 139. Mexico Anti-CD19, by Type USD Million (2023-2028)
  • Table 140. Mexico Anti-CD19, by Application USD Million (2023-2028)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-CD19: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-CD19: by Application USD Million (2017-2022)
  • Figure 6. South America Anti-CD19 Share (%), by Country
  • Figure 7. Asia Pacific Anti-CD19 Share (%), by Country
  • Figure 8. Europe Anti-CD19 Share (%), by Country
  • Figure 9. MEA Anti-CD19 Share (%), by Country
  • Figure 10. North America Anti-CD19 Share (%), by Country
  • Figure 11. Global Anti-CD19 share by Players 2022 (%)
  • Figure 12. Global Anti-CD19 share by Players (Top 3) 2022(%)
  • Figure 13. Global Anti-CD19 share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 17. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 18. Serum Institute of India (India) Revenue: by Geography 2022
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2022
  • Figure 21. Morphosys AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Morphosys AG (Germany) Revenue: by Geography 2022
  • Figure 23. Xencor, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Xencor, Inc (United States) Revenue: by Geography 2022
  • Figure 25. Seattle Genetics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Seattle Genetics, Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Affimed GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Affimed GmbH (Germany) Revenue: by Geography 2022
  • Figure 29. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 31. Bellicum Phamaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bellicum Phamaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 33. Cellular Biomedicine Group (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cellular Biomedicine Group (United States) Revenue: by Geography 2022
  • Figure 35. Global Anti-CD19: by Type USD Million (2023-2028)
  • Figure 36. Global Anti-CD19: by Application USD Million (2023-2028)
  • Figure 37. South America Anti-CD19 Share (%), by Country
  • Figure 38. Asia Pacific Anti-CD19 Share (%), by Country
  • Figure 39. Europe Anti-CD19 Share (%), by Country
  • Figure 40. MEA Anti-CD19 Share (%), by Country
  • Figure 41. North America Anti-CD19 Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Serum Institute of India (India)
  • Bristol-Myers Squibb Company (United States)
  • Morphosys AG (Germany)
  • Xencor, Inc (United States)
  • Seattle Genetics, Inc. (United States)
  • Affimed GmbH (Germany)
  • Bayer AG (Germany)
  • Bellicum Phamaceuticals, Inc. (United States)
  • Cellular Biomedicine Group (United States)
Additional players considered in the study are as follows:
Amgen Inc. (United States) , Sanofi S.A. (France) , Bharat Biotech (India) , Bio-Rad Laboratories, Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2023 229 Pages 66 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-CD19 Market Quantitative research analysis
Global Anti-CD19 Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Anti-CD19 Market are by type [Antibody Drug Conjugates, Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies), Engineered Antibodies and Bispecific Antibody (BsAb)], by end use application [Hospitals and Laboratories].
The Anti-CD19 Market is gaining popularity and expected to see strong valuation by 2028.
  • Technical Progress in Biotechnology Industry
  • Rising Demand for Antibody Drug Conjugates

Know More About Global Anti-CD19 Market Report?

Have a Query? Click Here

Other Related Reports

Tool Enzyme Comprehensive Study by Application (Nucleic Acid Amplification Testing, Protein and Small Molecule Detection, Other), Category (DNA Restriction Endonuclease, Ligase, Polymerase, Nuclease,...
$ 3450
Ligand Binding Assay Comprehensive Study by Type (Antigen Discovery Inc, Radioactive, Non-Radioactive), Application (Biomedical Research, Drug Discovery, Others) Players and Region - Global Market Ou...
$ 3500
Enzyme Indicators Comprehensive Study by Application (Bio-decontamination, Drug Development, Pesticide synthesis), End Use (Biopharma Industries, Ambulatory Surgical Centers, Hospitals And Clinics, D...
$ 3350
Whole Genome Amplification Comprehensive Study by Type (Single Cell WGA Kit, Complete WGA Kit, WGA Reamplification Kit, WGA and Chip DNA Kit, Others), Application (Drug Discovery and Development, Dis...
$ 3650
Enzyme Markers Comprehensive Study by Type (Industrial Enzymes, Specialty Enzymes), Application (Food and Beverages, Meat processing products, Dairy products, Beverages, Bakery & confectionary, Nutra...
$ 3450
Vectorized Antibodies Comprehensive Study by End Use (Hospitals, Specialized Clinics, Biotech Companies), Age Group (Paediatric, Adult, Geriatrics), Delivery Type (Adenoassociated Virus Vector, Elect...
$ 3350